Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Platform
Precision protein engineering generates superior molecules

Products
4 product candidates in the clinic as a result of research innovations

Partners
Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)

People
Great people making excellence happen, every day!
Technology
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.

Recent News
Bill Newell, CEO Interviewed by Biotech 2050
Episode 47. Next Generation Cell Free Cancer and Autoimmune Therapeutics, Bill Newell, CEO, Sutro Biopharma
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...